Fas (APO-1/CD95) is the prototypic death receptor, and the molecular mechanisms of Fas-induced apoptosis are comparably well understood. Here, we show that Fas activates NFκB via a pathway involving RIP, FADD, and caspase-8. Remarkably, the enzymatic activity of the latter was dispensable for Fas-induced NFκB signaling pointing to a scaffolding-related function of caspase-8 in nonapoptotic Fas signaling. NFκB was activated by overexpressed FLIPL and FLIPS in a cell type–specific manner. However, in the context of Fas signaling both isoforms blocked FasL-induced NFκB activation. Moreover, down-regulation of both endogenous FLIP isoforms or of endogenous FLIPL alone was sufficient to enhance FasL-induced expression of the NFκB target gene IL8. As NFκB signaling is inhibited during apoptosis, FasL-induced NFκB activation was most prominent in cells that were protected by Bcl2 expression or caspase inhibitors and expressed no or minute amounts of FLIP. Thus, protection against Fas-induced apoptosis in a FLIP-independent manner converted a proapoptotic Fas signal into an inflammatory NFκB-related response.
Skip Nav Destination
Article navigation
2 August 2004
Article|
August 02 2004
NFκB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP
Sebastian Kreuz,
Sebastian Kreuz
1Institute of Cell Biology and Immunology, University of Stuttgart, 70569 Stuttgart, Germany
Search for other works by this author on:
Daniela Siegmund,
Daniela Siegmund
1Institute of Cell Biology and Immunology, University of Stuttgart, 70569 Stuttgart, Germany
Search for other works by this author on:
Jost-Julian Rumpf,
Jost-Julian Rumpf
2Department of Molecular Internal Medicine, Medical Polyclinic, University of Wuerzburg, 97070 Wuerzburg, Germany
Search for other works by this author on:
Dierk Samel,
Dierk Samel
1Institute of Cell Biology and Immunology, University of Stuttgart, 70569 Stuttgart, Germany
Search for other works by this author on:
Martin Leverkus,
Martin Leverkus
3Department of Dermatology, University of Wuerzburg Medical School, 97080 Wuerzburg, Germany
Search for other works by this author on:
Ottmar Janssen,
Ottmar Janssen
4Institute of Immunology, Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany
Search for other works by this author on:
Georg Häcker,
Georg Häcker
5Institute for Medical Microbiology, Immunology, and Hygiene, Technical University Munich, 81675 Munich, Germany
Search for other works by this author on:
Oliver Dittrich-Breiholz,
Oliver Dittrich-Breiholz
6Institute of Pharmacology, Medical School Hannover, 30625 Hannover, Germany
Search for other works by this author on:
Michael Kracht,
Michael Kracht
6Institute of Pharmacology, Medical School Hannover, 30625 Hannover, Germany
Search for other works by this author on:
Peter Scheurich,
Peter Scheurich
1Institute of Cell Biology and Immunology, University of Stuttgart, 70569 Stuttgart, Germany
Search for other works by this author on:
Harald Wajant
Harald Wajant
2Department of Molecular Internal Medicine, Medical Polyclinic, University of Wuerzburg, 97070 Wuerzburg, Germany
Search for other works by this author on:
Sebastian Kreuz
1Institute of Cell Biology and Immunology, University of Stuttgart, 70569 Stuttgart, Germany
Daniela Siegmund
1Institute of Cell Biology and Immunology, University of Stuttgart, 70569 Stuttgart, Germany
Jost-Julian Rumpf
2Department of Molecular Internal Medicine, Medical Polyclinic, University of Wuerzburg, 97070 Wuerzburg, Germany
Dierk Samel
1Institute of Cell Biology and Immunology, University of Stuttgart, 70569 Stuttgart, Germany
Martin Leverkus
3Department of Dermatology, University of Wuerzburg Medical School, 97080 Wuerzburg, Germany
Ottmar Janssen
4Institute of Immunology, Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany
Georg Häcker
5Institute for Medical Microbiology, Immunology, and Hygiene, Technical University Munich, 81675 Munich, Germany
Oliver Dittrich-Breiholz
6Institute of Pharmacology, Medical School Hannover, 30625 Hannover, Germany
Michael Kracht
6Institute of Pharmacology, Medical School Hannover, 30625 Hannover, Germany
Peter Scheurich
1Institute of Cell Biology and Immunology, University of Stuttgart, 70569 Stuttgart, Germany
Harald Wajant
2Department of Molecular Internal Medicine, Medical Polyclinic, University of Wuerzburg, 97070 Wuerzburg, Germany
Address correspondence to H. Wajant, Dept. of Molecular Medicine, Medical Polyclinic, University of Wuerzburg, Roentgenring 11, 97070 Wuerzburg, Germany. Tel.: 49-931-201-71010. Fax: 49-931-201-71070. email: [email protected]
Abbreviations used in this paper: CHX, cycloheximide; DISC, death-inducing signaling complex; IAP, inhibitor of apoptosis; RPA, RNase protection assay; siRNA, small interfering RNA.
Received:
January 09 2004
Accepted:
June 23 2004
Online ISSN: 1540-8140
Print ISSN: 0021-9525
The Rockefeller University Press
2004
J Cell Biol (2004) 166 (3): 369–380.
Article history
Received:
January 09 2004
Accepted:
June 23 2004
Citation
Sebastian Kreuz, Daniela Siegmund, Jost-Julian Rumpf, Dierk Samel, Martin Leverkus, Ottmar Janssen, Georg Häcker, Oliver Dittrich-Breiholz, Michael Kracht, Peter Scheurich, Harald Wajant; NFκB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP . J Cell Biol 2 August 2004; 166 (3): 369–380. doi: https://doi.org/10.1083/jcb.200401036
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement
Advertisement